Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

About this update from Dianthus Therapeutics, Inc.

NEW YORK and WALTHAM, Mass. , Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT . Investor Webcast & Conference Call Information To access the live conference call by phone, please register here . Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN. A live webcast may be accessed through the Investors and Media section of the Company’s website, www.dianthustx.com . Following the call, a replay will be available at the same location. About Dianthus Therapeutics Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass. , Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn . Contact Jennifer Davis Ruff Dianthus Therapeutics [email protected] Source: Dianthus Therapeutics, Inc.

View stock analysis, news, and events for Dianthus Therapeutics, Inc.